Cabaletta Bio (CABA) Expected to Announce Quarterly Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cabaletta Bio to post earnings of ($0.4579) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $3.43 on Thursday. The stock’s fifty day simple moving average is $2.62 and its 200 day simple moving average is $2.39. Cabaletta Bio has a one year low of $0.99 and a one year high of $3.78. The firm has a market cap of $330.17 million, a price-to-earnings ratio of -1.36 and a beta of 3.25.

Insider Activity at Cabaletta Bio

In related news, Director Mark Simon purchased 11,061 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was acquired at an average price of $2.28 per share, with a total value of $25,219.08. Following the completion of the acquisition, the director directly owned 147,205 shares in the company, valued at approximately $335,627.40. This trade represents a 8.12% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Nichtberger acquired 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the transaction, the chief executive officer directly owned 1,031,483 shares in the company, valued at $2,310,521.92. The trade was a 4.56% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 127,668 shares of company stock worth $286,211. 11.25% of the stock is owned by insiders.

Institutional Investors Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Comerica Bank boosted its stake in Cabaletta Bio by 2,292.1% in the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after acquiring an additional 39,860 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Cabaletta Bio in the 4th quarter valued at $58,000. Tower Research Capital LLC TRC boosted its position in shares of Cabaletta Bio by 695.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock worth $78,000 after purchasing an additional 44,621 shares during the last quarter. Invesco Ltd. boosted its position in shares of Cabaletta Bio by 357.1% in the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock worth $85,000 after purchasing an additional 48,181 shares during the last quarter. Finally, LPL Financial LLC acquired a new stake in shares of Cabaletta Bio during the fourth quarter worth $93,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.25.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.